{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:27:49Z","timestamp":1785306469839,"version":"3.55.0"},"reference-count":32,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,11,1]]},"abstract":"<jats:p>Objective. There is little data regarding safety or efficacy of Crotalinae polyvalent immune Fab (ovine) antivenom (crotaline Fab) in pediatric patients. Our objective was to provide the first information regarding safety and effectiveness of this new drug in children.<\/jats:p>\n               <jats:p>Methods. Data were collected prospectively and retrospectively for all consecutive pediatric patients bitten by rattlesnakes and treated at 2 urban hospitals during 2001. Cases were included if there were signs of envenomation at presentation, patient age was 13 years or less, and there was administration of crotaline Fab. Cases were excluded if antivenin (Crotalidae) polyvalent (equine origin, the conventional antivenom) was given. Primary outcome variables were snakebite severity scores throughout the course of therapy, number of vials of crotaline Fab administered, occurrence of allergic reactions, adjunct surgical therapy, and the presence of permanent sequelae or serum sickness identified at follow-up.<\/jats:p>\n               <jats:p>Results. In the 12 cases studied, ages ranged from 14 months to 13 years (mean: 6.9; standard deviation: 4.2). Presentation snakebite severity scores ranged from 2 to 9 (mean: 5.3; standard deviation: 2.3). Total crotaline Fab doses ranged from 4 to 22 vials (mean: 12.7; standard deviation: 5.4). Initial control of symptoms was achieved with 4 to 16 vials (mean: 7.7; standard deviation: 3.7), and severity scores stabilized or improved within 24 hours in all patients. Recurrence of local swelling occurred in 1 case despite scheduled repeat doses of antivenom. No cases required surgical intervention, and no permanent sequelae were identified. No immediate or delayed hypersensitivity reactions occurred.<\/jats:p>\n               <jats:p>Conclusion. In this group of pediatric patients treated for rattlesnake envenomation, crotaline Fab antivenom was safe and seemed to be effective.<\/jats:p>","DOI":"10.1542\/peds.110.5.968","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"968-971","source":"Crossref","is-referenced-by-count":67,"title":["Crotaline Fab Antivenom for the Treatment of Children With Rattlesnake Envenomation"],"prefix":"10.1542","volume":"110","author":[{"given":"Steven R.","family":"Offerman","sequence":"first","affiliation":[{"name":"Division of Medical Toxicology, Department of Emergency Medicine UCSD Medical Center, San Diego, California"},{"name":"San Diego Division of California Poison Control System, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Bush","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Loma Linda University School of Medicine, Medical Center and Children\u2019s Hospital, Loma Linda, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Moynihan","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Loma Linda University School of Medicine, Medical Center and Children\u2019s Hospital, Loma Linda, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Clark","sequence":"additional","affiliation":[{"name":"Division of Medical Toxicology, Department of Emergency Medicine UCSD Medical Center, San Diego, California"},{"name":"San Diego Division of California Poison Control System, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2002,11,1]]},"reference":[{"key":"2021121006390385200_R1","doi-asserted-by":"crossref","unstructured":"Litovitz TL, Klein-Schwartz W, White S, et al. 2000 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med.2001;19:337\u2013395","DOI":"10.1053\/ajem.2001.25272"},{"key":"2021121006390385200_R2","doi-asserted-by":"crossref","unstructured":"Lovecchio F, Debus DM. Snakebite envenomation in children: a 10-year retrospective review. Wild Environ Med.2001;12:184\u2013189","DOI":"10.1580\/1080-6032(2001)012[0184:SEICAY]2.0.CO;2"},{"key":"2021121006390385200_R3","unstructured":"Wingert WA, Chan L. Rattlesnake bites in Southern California and rationale for recommended treatment. West J Med.1988;148:37\u201344"},{"key":"2021121006390385200_R4","unstructured":"Norris RL, Bush SP. North American venomous reptile bites. In: Auerbach P, ed. Wilderness Medicine: Management of Wilderness and Environmental Emergencies. St Louis, MO: Mosby;2001:986\u2013926"},{"key":"2021121006390385200_R5","doi-asserted-by":"crossref","unstructured":"Parrish HM. Incidence of treated snakebites in the United States. Public Health Rep.1966;81:269\u2013276","DOI":"10.2307\/4592691"},{"key":"2021121006390385200_R6","doi-asserted-by":"crossref","unstructured":"Tanen DA, Ruha AM, Graeme KA, et al. Epidemiology and hospital course of rattlesnake envenomations cared for at a tertiary referral center in central Arizona. Acad Emerg Med.2001;8:177\u2013182","DOI":"10.1111\/j.1553-2712.2001.tb01284.x"},{"key":"2021121006390385200_R7","doi-asserted-by":"crossref","unstructured":"Parrish HM, Goldner JC, Silberg SL. Comparison between snakebites in children and adults. Pediatrics.1965;36:251\u2013256","DOI":"10.1542\/peds.36.2.251"},{"key":"2021121006390385200_R8","doi-asserted-by":"crossref","unstructured":"Consroe P, Egan NB, Russell RE, et al. Comparison of a new ovine antigen binding fragment (Fab) for United States crotalidae with the commercial antivenin for protection against venom-induced lethality in mice. Am J Trop Med Hyg.1995;53:507\u2013510","DOI":"10.4269\/ajtmh.1995.53.507"},{"key":"2021121006390385200_R9","doi-asserted-by":"crossref","unstructured":"Dart RC, Seifert SA, Carroll L, et al. Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid poisoning. Ann Emerg Med.1997;30:33\u201339","DOI":"10.1016\/S0196-0644(97)70107-0"},{"key":"2021121006390385200_R10","doi-asserted-by":"crossref","unstructured":"Seifert SA, Boyer LV, Dart RC, et al. Relationship of venom effects to venom antigen and antivenom serum concentrations in a patient with Crotalus atrox envenomation treated with Fab antivenom. Ann Emerg Med.1997;30:49\u201353","DOI":"10.1016\/S0196-0644(97)70110-0"},{"key":"2021121006390385200_R11","doi-asserted-by":"crossref","unstructured":"Clark RF, Williams SR, Nordt SP, et al. Successful treatment of crotalid-induced neurotoxicity with a new polyspecific crotalid Fab antivenom. Ann Emerg Med.1997;30:54\u201357","DOI":"10.1016\/S0196-0644(97)70111-2"},{"key":"2021121006390385200_R12","doi-asserted-by":"crossref","unstructured":"Fazio A. Fab fragments in the treatment of digoxin overdose: pediatric considerations. South Med J.1987;80:1553\u20131556","DOI":"10.1097\/00007611-198712000-00016"},{"key":"2021121006390385200_R13","doi-asserted-by":"crossref","unstructured":"Dart RC, Hurlbut KM, Garcia R, et al. Validation of a severity score for the assessment of crotalid snakebite. Ann Emerg Med.1996;27:321\u2013326","DOI":"10.1016\/S0196-0644(96)70267-6"},{"key":"2021121006390385200_R14","doi-asserted-by":"crossref","unstructured":"Minton SA. Polyvalent antivenin in the treatment of experimental snake venom poisoning. Am J Trop Med Hyg.1954;3:1077\u20131082","DOI":"10.4269\/ajtmh.1954.3.1077"},{"key":"2021121006390385200_R15","doi-asserted-by":"crossref","unstructured":"Russell FE, Ruzic N, Gonzalez H. Effectiveness of antivenin (crotalidae) polyvalent following injection of crotalus venom. Toxicon.1973;11:461\u2013464","DOI":"10.1016\/0041-0101(73)90003-2"},{"key":"2021121006390385200_R16","doi-asserted-by":"crossref","unstructured":"Dart RC, Goldner A, Lindsey D. Efficacy of post envenomation administration of antivenin. Toxicon.1988;26:1218\u20131221","DOI":"10.1016\/0041-0101(88)90308-X"},{"key":"2021121006390385200_R17","doi-asserted-by":"crossref","unstructured":"Brubacher JR, Lachman D, Hoffman RS. Efficacy of Wyeth polyvalent antivenin used in the pretreatment of copperhead envenomation in mice. Wild Environ Med.1999;10:142\u2013145","DOI":"10.1580\/1080-6032(1999)010[0142:EOWPAU]2.3.CO;2"},{"key":"2021121006390385200_R18","doi-asserted-by":"crossref","unstructured":"Russell FE, Carlson RW, Wainschel J, et al. Snake venom poisoning in the United States. JAMA.1975;233:341\u2013344","DOI":"10.1001\/jama.233.4.341"},{"key":"2021121006390385200_R19","doi-asserted-by":"crossref","unstructured":"Riffer E, Curry SC, Gerkin R. Successful treatment with antivenin of marked thrombocytopenia without significant coagulopathy following rattlesnake bite. Ann Emerg Med.1987;16:1297\u20131299","DOI":"10.1016\/S0196-0644(87)80245-7"},{"key":"2021121006390385200_R20","doi-asserted-by":"crossref","unstructured":"Rosen PB, Leiva JI, Ross CP. Delayed antivenin treatment for a patient after envenomation with Crotalus atrox. Ann Emerg Med.2000;35:86\u201388","DOI":"10.1016\/S0196-0644(00)70111-9"},{"key":"2021121006390385200_R21","doi-asserted-by":"crossref","unstructured":"Burgess JL, Dart RC. Snake venom coagulopathy: use and abuse of blood products in the treatment of pit viper envenomation. Ann Emerg Med.1991;20:795\u2013801","DOI":"10.1016\/S0196-0644(05)80845-5"},{"key":"2021121006390385200_R22","doi-asserted-by":"crossref","unstructured":"Jurkovich GJ, Luterman A, McCullar K. Complications of crotalidae antivenin therapy. J Trauma.1988;28:1032\u20131037","DOI":"10.1097\/00005373-198807000-00020"},{"key":"2021121006390385200_R23","doi-asserted-by":"crossref","unstructured":"Seiler JG, Sagerman SD, Geller RJ, et al. Venomous snake bite: current concepts of treatment. Orthopedics.1994;17:707\u2013714","DOI":"10.3928\/0147-7447-19940801-10"},{"key":"2021121006390385200_R24","doi-asserted-by":"crossref","unstructured":"Burch JM, Agarwal R, Mattox KL, et al. The treatment of crotalid envenomation without antivenin. J Trauma.1988;28:35\u201343","DOI":"10.1097\/00005373-198801000-00005"},{"key":"2021121006390385200_R25","doi-asserted-by":"crossref","unstructured":"Wagner CW, Golladay ES. Crotalid envenomation in children: selective conservative management. J Pediatr Surg.1989;24:128\u2013131","DOI":"10.1016\/S0022-3468(89)80317-3"},{"key":"2021121006390385200_R26","unstructured":"CroFab [package insert]. Nashville, TN: Protherics Inc;2000"},{"key":"2021121006390385200_R27","doi-asserted-by":"crossref","unstructured":"Boyer LV, Seifert SA, Clark RF, et al. Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med.1999;159:706\u2013710","DOI":"10.1001\/archinte.159.7.706"},{"key":"2021121006390385200_R28","doi-asserted-by":"crossref","unstructured":"Ruha AM, Curry SC, Beuhler M, et al. Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation. Ann Emerg Med.2002;39:609\u2013615","DOI":"10.1067\/mem.2002.123698"},{"key":"2021121006390385200_R29","doi-asserted-by":"crossref","unstructured":"Clark RF, McKinney PE, Chase PB, et al. Immediate and delayed reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. Ann Emerg Med.2002;39:671\u2013676","DOI":"10.1067\/mem.2002.123134"},{"key":"2021121006390385200_R30","doi-asserted-by":"crossref","unstructured":"Bogdan GM, Dart RC, Falbo SC, et al. Recurrent coagulopathy after antivenom treatment of crotalid snakebite. South Med J.2000;93:562\u2013566","DOI":"10.1097\/00007611-200006000-00003"},{"key":"2021121006390385200_R31","doi-asserted-by":"crossref","unstructured":"Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotaline polyvalent immune Fab (ovine) antivenom for the treatment of crotaline snakebite in the United States. Arch Intern Med.2001;161:2030\u20132036","DOI":"10.1001\/archinte.161.16.2030"},{"key":"2021121006390385200_R32","doi-asserted-by":"crossref","unstructured":"Brent J. Toxicologists and the assessment of risk: the problem with mercury. Clin Toxicol.2001;39:707\u2013710","DOI":"10.1081\/CLT-100108511"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/110\/5\/968\/1116531\/pe1102000968.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/110\/5\/968\/1116531\/pe1102000968.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T15:20:54Z","timestamp":1639149654000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/110\/5\/968\/64511\/Crotaline-Fab-Antivenom-for-the-Treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2002,11,1]]},"published-print":{"date-parts":[[2002,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.110.5.968","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11,1]]}}}